Picture of AstraZeneca logo

AZN — AstraZeneca News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Brief: Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

BRIEF-Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

- Summit Therapeutics Inc. SMMT.O:

  • SUMMIT THERAPEUTICS PROVIDES UPDATE REGARDING IVONESCIMAB BIOLOGICS LICENSE APPLICATION

  • SUMMIT THERAPEUTICS - FDA CANNOT APPROVE IVONESCIMAB BLA DUE TO LACK OF STATISTICALLY SIGNIFICANT OS IMPROVEMENT

  • SUMMIT THERAPEUTICS - HARMONI PHASE III STUDY SHOWS STATISTICALLY SIGNIFICANT PFS IMPROVEMENT

  • SUMMIT THERAPEUTICS - IVONESCIMAB PLUS CHEMOTHERAPY DEMONSTRATES ACCEPTABLE SAFETY PROFILE

  • SUMMIT THERAPEUTICS - DEVELOPING IVONESCIMAB IN NSCLC, CRC, UC, RCC WITH PHASE II/III TRIALS

  • SUMMIT THERAPEUTICS - COLLABORATES WITH ASTRAZENECA AND DAIICHI SANKYO ON IVONESCIMAB COMBINATIONS

Source text: ID:nBw8mvwbWa

Further company coverage: SMMT.O


((Reuters.Briefs@thomsonreuters.com;))

Recent news on AstraZeneca

See all news